ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: This compound reduces BCR-ABL protein levels and disrupts its downstream signaling, leading to decreased proliferation and increased maturation of leukemic cells, thus, indicating its potential as a therapeutic approach for resistant CML cases [44].